Xilio TherapeuticsXLO
13F holders, Q1 2026 (March 31)23holders
1famous investor
$8.41avg. 13F price*
At the end of Q1 2026, 23 institutions reported holding Xilio Therapeutics Inc. (XLO) in their 13F filings. The largest holders were Bain Capital Life Sciences Investors, LLC ($5.6M), Frazier Life Sciences Management, L.P. ($3.6M) and Sio Capital Management, LLC ($1.3M). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Xilio Therapeutics Inc.
- CUSIP
- 98422T209
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $981K |
| Exits | 0 | $0 |
Ownership 23 holders
| Bain Capital Life Sciences Investors, LLC | 0.50% | Add +26.1% | 664,021 | $5.6M |
| Frazier Life Sciences Management, L.P. | 0.09% | No change | 422,505 | $3.6M |
| Sio Capital Management, LLC | 0.18% | No change | 152,464 | $1.3M |
| Vanguard Capital Management LLC | 0.00% | — | 123,660 | $1.0M |
| Caligan Partners LP | 0.07% | New | 112,128 | $943K |
| Merck & Co., Inc. | 0.26% | No change | 105,982 | $891K |
| Stonepine Capital Management, LLC | 0.47% | Add +611.4% | 64,162 | $540K |
| Morgan Stanley | 0.00% | Reduce -4.2% | 57,493 | $484K |
| Renaissance Technologies | 0.00% | Add +101.5% | 49,566 | $417K |
| AJU IB Investment Co., Ltd. | 1.31% | No change | 47,695 | $401K |
| Geode Capital Management, LLC | 0.00% | Add +58.3% | 37,197 | $313K |
| FMR LLC | 0.00% | No change | 36,558 | $307K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 28,475 | $239K |
| Gsa Capital Partners LLP | 0.01% | Add +60.3% | 16,946 | $143K |
| Velan Capital Investment Management LP | 0.08% | Add +17.6% | 14,285 | $120K |
| Ghisallo Capital Management LLC | 0.00% | Reduce -82.6% | 13,800 | $116K |
| State Street Corp. | 0.00% | No change | 13,311 | $112K |
| Cwm, LLC | 0.00% | New | 4,206 | $35K |
| UBS Group AG | 0.00% | Add +27748.4% | 4,038 | $34K |
| JPMorgan Chase & Co. | 0.00% | New | 240 | $2K |
| Vanguard Global Advisers, LLC | 0.00% | — | 210 | $2K |
| Royal Bank of Canada | 0.00% | New | 91 | $1K |
| Key Financial Inc | 0.00% | Reduce -0.5% | 59 | $496 |
"% of holder's portfolio" is XLO's weight in each manager's 13F, not the share of Xilio Therapeutics Inc. the manager owns.